Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hospital Corporation of China Limited

弘和仁愛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3869)

ANNOUNCEMENT OF RE-DESIGNATION OF DIRECTORS AND CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that with effect from November 20, 2020:

- (1) Mr. CHEN Shuai, a non-executive Director, has been re-designated as an executive Director;
- (2) Mr. SU Zhiqiang, an executive Director, has been re-designated as a non-executive Director;
- (3) Mr. SU Zhiqiang has resigned as an Authorised Representative; and
- (4) Mr. CHEN Shuai has been appointed as an Authorised Representative.

The board (the "Board") of directors (the "Directors" and each a "Director") of Hospital Corporation of China Limited (the "Company" and together with its subsidiaries, the "Group") hereby announces that with effect from November 20, 2020, (i) Mr. CHEN Shuai ("Mr. Chen"), a non-executive Director, has been re-designated as an executive Director; (ii) Mr. SU Zhiqiang ("Mr. Su"), an executive Director, has been re-designated as a non-executive Director; (iii) Mr. Su has resigned as an authorized representative of the Company (the "Authorised Representative") under Rule 3.05 of the Rules (the "Listing Rules") Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited due to work arrangements; and (iv) Mr. Chen has been appointed as an Authorized Representative.

Mr. Su has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as an Authorised Representative that needs to be brought to the attention of the shareholders of the Company.

Set out below are the biographies of Mr. Chen and Mr. Su and other information to be disclosed pursuant to Rule 13.51(2) of the Listing Rules:

Mr. CHEN Shuai

Mr. Chen, aged 46, has been a non-executive Director, the chairman of the Board and acting chief executive officer of the Company since June 2020 and has extensive experience in investment management, supplier management and retail business. He joined Hony Capital (a series of private equity investment funds, together with their respective management companies/general partners, "Hony Capital") in 2003 and has served as a managing director of Hony Capital since 2011. Mr. Chen also currently serves as the deputy general manager of the private equity investment department and a member of the private equity business steering committee of Hony Capital, as well as general manager of Hony Capital's Shanghai platform. Prior to joining Hony Capital, Mr. Chen was the senior financial manager of Wumart Stores, Inc., general manager of the vendor management department of Beijing Jiahe Group (北京家和集團), and senior investment manager of the investment management department and urban strategic circulation department of D'Long International Strategic Investment Company.

Mr. Chen is currently a non-executive director of China Rongzhong Financial Holdings Company Limited (HKEX Stock Code: 3963), a non-executive director of Century Ginwa Retail Holdings Limited (HKEX Stock Code: 162) and a director of Shanghai Chengtou Holding Co., Ltd. (Shanghai Stock Exchange Stock Code: 600649). He was a director of Shanghai Environment Group Co., Ltd. (Shanghai Stock Exchange Stock Code: 601200) from February 2017 to September 2019. Mr. Chen is also a member of the 11th Finance Sector Youth Union (青聯金融界別) of Shanghai and the 7th Merger and Reorganization Committee (併購重組委) of the China Securities Regulatory Commission.

Mr. Chen obtained his bachelor's degree in economics from Beijing Forestry University in 1997, and a Master of Business Administration from the China Europe International Business School in 2010.

The current appointment letter for Mr. Chen being a non-executive Director will be terminated upon his re-designation as an executive Director on November 20, 2020. The Company will enter into a new service contract with Mr. Chen in respect of his re-designation as an executive Director for an initial term of 3 years, during which he shall be subject to retirement and re-election in accordance with the memorandum and articles of association of the Company (the "Articles"). Accordingly, Mr. Chen will only hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting of the Company in accordance with the Articles.

Mr. Chen will not receive any remuneration for acting as an executive Director.

Mr. SU Zhiqiang

Mr. Su, aged 37, has been an executive Director Since June 2020. He joined Hony Capital in 2017 and serves as the investment director of the private equity investment department, with a focus on coverage of healthcare related fields of investment. Mr. Su also serves as a director of Shanghai Weikang Investment Management Co., Ltd., New Pride Holdings Limited, Ever Surpass Investments Limited, Acute Sky Holdings Limited, Bliss Success Holdings Limited, Impeccable Success Limited and Oriental Ally Holdings Limited, all are subsidiaries of the Company, and a council member of Shanghai Yangsi Hospital, a hospital founded by Shanghai Weikang Investment Management Co., Ltd. Prior to joining Hony Capital, Mr. Su worked in the investment management department of China Minmetals Corporation from 2009 to 2011 and in the investment department of CITIC Private Equity Funds Management Co., Ltd. from 2011 to 2013. Mr. Su subsequently served as an investment director at Sino-Rock Investment Management Company Limited, which is affiliated to China Cinda Asset Management Co., Ltd. (HKEX Stock Code: 1359), from 2014 to 2017.

Mr. Su obtained his bachelor's degree in financial engineering from Shandong University in June 2006, and a master's degree in finance from the Central University of Finance and Economics in June 2009.

The current service contract for Mr. Su as an executive Director will be terminated upon his re-designation as a non-executive Director on November 20, 2020. The Company will execute an appointment letter for Mr. Su's re-designation as a non-executive Director for an initial term of 3 years, during which he shall be subject to retirement and re-election in accordance with the Articles. Accordingly, Mr. Su will only hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting of the Company in accordance with the Articles.

Mr. Su will not receive any remuneration for acting as a non-executive Director.

As at the date of this announcement, Mr. Chen and Mr. Su (i) do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) do not hold any position in the Company or members of the Group other than those disclosed above; and (iii) do not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed above, there is no further information relating to the re-designations of Mr. Chen and Mr. Su that needs to be disclosed and brought to the attention of the shareholders of the Company pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

By order of the Board
Hospital Corporation of China Limited
Chen Shuai
Chairman

Beijing, China, November 20, 2020

As at the date of this announcement, the Directors of the Company are Mr. CHEN Shuai and Mr. LU Wenzuo being the executive Directors; Mr. SU Zhiqiang, Ms. SHI Wenting, Ms. LIU Lu and Ms. WANG Nan being the non-executive Directors; and Mr. DANG Jinxue, Mr. SHI Luwen and Mr. ZHOU Xiangliang being the independent non-executive Directors.